Financial_NNP record_NN Quarterly_JJ trend_NN An_DT unaudited_JJ analysis_NN is_VBZ provided_VBN by_IN quarter_NN of_IN the_DT Group_NNP results_NNS in_IN sterling_NN for_IN the_DT financial_JJ year_NN 2005_CD ._.
The_DT analysis_NN comprises_VBZ statutory_JJ results_NNS and_CC pharmaceutical_JJ sales_NNS by_IN therapeutic_JJ area_NN ._.
GSK_NNP Annual_JJ Report_NNP 2005_CD 177_CD INVESTOR_NN INFORMATION_NNP Financial_NNP record_NN continued_VBD Five_CD year_NN record_NN A_DT record_NN of_IN financial_JJ performance_NN is_VBZ provided_VBN analyzed_VBN in_IN accordance_NN with_IN current_JJ reporting_NN practice_NN ._.
The_DT transition_NN date_NN to_TO IFRS_NNP for_IN GlaxoSmithKline_NNP is_VBZ 1st_CD January_NNP 2003_CD ._.
Therefore_RB ,_, the_DT 2005_CD ,_, 2004_CD and_CC 2003_CD information_NN included_VBN in_IN the_DT Five_CD year_NN record_NN is_VBZ in_IN accordance_NN with_IN IFRS_NNP as_IN adopted_VBN for_IN use_NN in_IN the_DT European_NNP Union_NNP ._.
For_IN GSK_NNP there_EX are_VBP no_DT differences_NNS between_IN IFRS_NNP as_IN adopted_VBN for_IN use_NN in_IN the_DT European_NNP Union_NNP and_CC full_JJ IFRS_NNS as_IN published_VBN by_IN the_DT International_NNP Accounting_NNP Standards_NNP Board_NNP ._.
The_DT 2002_CD and_CC 2001_CD information_NN is_VBZ in_IN accordance_NN with_IN UK_NNP GAAP_NNP ._.
To_TO provide_VB a_DT link_NN between_IN IFRS_NNP and_CC UK_NNP GAAP_NNP ,_, 2003_CD information_NN is_VBZ also_RB presented_VBN under_IN UK_NNP GAAP_NNP ._.
The_DT accounting_NN policies_NNS used_VBN in_IN the_DT preparation_NN of_IN the_DT UK_NNP GAAP_NNP information_NN are_VBP disclosed_VBN in_IN the_DT 2004_CD Annual_JJ Report_NNP ._.
Information_NN prepared_VBN under_IN IFRS_NNP is_VBZ not_RB directly_RB comparable_JJ with_IN information_NN prepared_VBN under_IN UK_NNP GAAP_NNP ._.
The_DT Five_CD year_NN record_NN also_RB presents_VBZ information_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP ._.
Consumer_NNP healthcare_NN turnover_NN IFRS_NNP 2005 2004 2003_CD m_FW m_FW m_FW OTC_NNP medicines_NNS 1,437_CD 1,400_CD 1,472_CD Oral_NNP care_NN 943 913 915_CD Nutritional_NNP healthcare_NN 619 573 569_CD 2,999_CD 2,886_CD 2,956_CD Consumer_NN healthcare_NN turnover_NN UK_NNP GAAP_NNP 2003 2002 2001_CD m_FW m_FW m_FW OTC_NNP medicines_NNS 1,556_CD 1,586_CD 1,603_CD Oral_NNP care_NN 1,082_CD 1,052_CD 1,106_CD Nutritional_NNP healthcare_NN 622 579 575_CD 3,260_CD 3,217_CD 3,284_CD Financial_NNP results_NNS IFRS_NNP 2005 2004 2003_CD m_FW m_FW m_FW Turnover_NN 21,660_CD 19,986_CD 21,070_CD Operating_NN profit_NN 6,874_CD 5,756_CD 6,050_CD Profit_NN before_IN taxation_NN 6,732_CD 5,779_CD 5,954_CD Profit_NN after_IN taxation_NN 4,816_CD 4,022_CD 4,308_CD Basic_JJ earnings_NNS per_IN share_NN pence_NN 82.6_CD 68.1_CD p_NN 72.3_CD p_VBP Diluted_JJ earnings_NNS per_IN share_NN pence_NN 82.0_CD 68.0_CD p_NN 72.1_CD p_NN Weighted_VBN average_JJ number_NN of_IN shares_NNS in_IN issue_NN :_: Basic_JJ 5,674_CD 5,736_CD 5,806_CD Diluted_NNP 5,720_CD 5,748_CD 5,824_CD Return_NN on_IN capital_NN employed_VBN %_NN 99.7_CD 100.2_CD 116.6_CD Financial_NNP results_NNS UK_NNP GAAP_NNP 2003 2002 2001_CD m_FW m_FW m_FW Turnover_NN 21,441_CD 21,212_CD 20,489_CD Operating_NN profit_NN 6,376_CD 5,569_CD 4,701_CD Profit_NN before_IN taxation_NN 6,313_CD 5,524_CD 4,484_CD Profit_NN after_IN taxation_NN 4,584_CD 4,060_CD 3,158_CD Basic_JJ earnings_NNS per_IN share_NN pence_NN 77.1_CD p_NN 66.5_CD p_VBP 49.9_CD p_JJ Diluted_JJ earnings_NNS per_IN share_NN pence_NN 76.9_CD p_NN 66.3_CD p_VBP 49.5_CD p_JJ Weighted_JJ average_JJ number_NN of_IN shares_NNS in_IN issue_NN :_: Basic_JJ 5,806_CD 5,912_CD 6,064_CD Diluted_NNP 5,824_CD 5,934_CD 6,116_CD Return_NN on_IN capital_NN employed_VBN %_NN 120.8_CD 110.6_CD 75.6_CD Return_NN on_IN capital_NN employed_VBN is_VBZ calculated_VBN as_IN statutory_JJ profit_NN before_IN taxation_NN as_IN a_DT percentage_NN of_IN average_JJ capital_NN employed_VBN over_IN the_DT year_NN ._.
GSK_NNP Annual_JJ Report_NNP 2005_CD 179_CD INVESTOR_NN INFORMATION_NNP Financial_NNP record_NN continued_VBD 2005 2004 2003 2002_CD 2001_CD Amounts_NNS in_IN accordance_NN with_IN US_NNP GAAP_NNP m_FW m_FW m_FW m_FW m_FW Turnover_NN 21,660_CD 19,986_CD 21,117_CD 21,212_CD 20,489_CD Net_JJ income_NN loss_NN 3,336_CD 2,732_CD 2,420_CD 413_CD 143_CD Basic_JJ net_JJ income_NN loss_NN per_IN share_NN pence_NN 58.8_CD p_NN 47.6_CD p_VBP 41.7_CD p_JJ 7.0_CD p_NN 2.4_CD p_VBP Diluted_JJ net_JJ income_NN loss_NN per_IN share_NN pence_NN 58.3_CD p_NN 47.5_CD p_VBP 41.6_CD p_JJ 7.0_CD p_NN 2.4_CD p_NN The_DT information_NN presented_VBN in_IN accordance_NN with_IN US_NNP GAAP_NNP is_VBZ derived_VBN from_IN financial_JJ information_NN prepared_VBN under_IN IFRS_NNP ,_, as_IN adopted_VBN for_IN use_NN in_IN the_DT European_NNP Union_NNP ,_, for_IN 2003-2005_CD and_CC from_IN UK_NNP GAAP_NNP for_IN 2001-2002_CD ._.
The_DT information_NN below_IN presents_NNS US_NNP GAAP_NNP net_JJ income_NN loss_NN and_CC net_JJ income_NN loss_NN per_IN share_NN as_IN if_IN the_DT results_NNS for_IN the_DT year_NN ended_VBD 31st_CD December_NNP 2001_CD were_VBD adjusted_VBN to_TO reverse_VB the_DT amortisation_NN expense_NN for_IN goodwill_NN and_CC indefinite-lived_JJ intangible_JJ assets_NNS ,_, that_DT is_VBZ ,_, as_IN if_IN SFAS_NNP 142_CD had_VBD also_RB applied_VBN in_IN those_DT years_NNS ._.
2001_CD m_NN Adjusted_VBN net_JJ income_NN loss_NN 1,456_CD Adjusted_VBN basic_JJ net_JJ income_NN loss_NN per_IN share_NN pence_NN 24.0_CD p_NN Adjusted_VBN diluted_JJ net_JJ income_NN loss_NN per_IN share_NN pence_NN 23.8_CD p_NNP Exchange_NNP rates_NNS As_IN a_DT guide_NN to_TO holders_NNS of_IN ADRs_NNS ,_, the_DT following_VBG tables_NNS set_VBN out_RP ,_, for_IN the_DT periods_NNS indicated_VBD ,_, information_NN on_IN the_DT exchange_NN rate_NN of_IN US_NNP dollars_NNS for_IN sterling_NN as_IN reported_VBN by_IN the_DT Federal_NNP Reserve_NNP Bank_NNP of_IN New_NNP York_NNP noon_NN buying_NN rate_NN ._.
2005 2004 2003 2002_CD 2001_CD Average_JJ 1.81_CD 1.84_CD 1.63_CD 1.51_CD 1.44_CD The_DT average_JJ rate_NN for_IN the_DT year_NN is_VBZ calculated_VBN as_IN the_DT average_NN of_IN the_DT noon_NN buying_NN rates_NNS on_IN the_DT last_JJ day_NN of_IN each_DT month_NN during_IN the_DT year_NN ._.
It_PRP excludes_VBZ those_DT employees_NNS who_WP are_VBP employed_VBN and_CC managed_VBN by_IN GlaxoSmithKline_NNP on_IN a_DT contract_NN basis_NN ._.
